Charles River Laboratories International, Inc.(CRL)Earnings, Financials & Key RatiosCharles River Laboratories International, Inc. (CRL) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's inability to maintain positive net income, coupled with a volatile operating cash flow to net income ratio of -2.77, suggests significant underlying operational risks.
Charles River Laboratories International, Inc. (CRL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Charles River Laboratories International, Inc. (CRL) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $2.06vs $1.96+5.1% | $996Mvs $977M+1.9% |
| Q1 2026 | Feb 18, 2026 | $2.39vs $2.33+2.6% | $994Mvs $987M+0.7% |
| Q4 2025 | Nov 5, 2025 | $2.43vs $2.32+4.7% | $1.0Bvs $987M+1.8% |
| Q3 2025 | Aug 6, 2025 | $3.12vs $2.50+24.8% | $1.0Bvs $969M+6.5% |
Recent stock market news and headlines for Charles River Laboratories International, Inc. (CRL)
Investors with an interest in Medical Services stocks have likely encountered both Labcorp Holdings (LH) and Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?
Charles River Laboratories International, Inc. CRL is well-poised to grow in the coming quarters owing to the strength of its Research Models and Services (“RMS”) business and broader CRADL adoption. Strategic deals continue to broaden its capabilities while streamlining its portfolio.
Achieve Life Sciences remains a cytisinicline story, with very positive smoking-cessation data. This also gives cytisinicline some added optionality for vaping. The FDA's CRL appears to be mostly about manufacturing and labeling issues. However, it's not about a particular cytisinicline efficacy or safety problem. ACHV is currently targeting Q4 2026 resubmission and, assuming everything goes according to plan, it could receive approval by 1H2027.
Bio-Rad Laboratories offers high profitability and a liquid balance sheet with a current ratio above 5x. Charles River Laboratories International maintains a leading scale in drug discovery services with over 19,000 employees globally.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). TuneLab was created to accelerate biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data, in exchange for data contributions that improve model performance through federated le.
Key metrics vs top competitors for Charles River Laboratories International, Inc. (CRL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $228.68 | $11.01B | -78.58 | -0.85% | -3.59% | -4.3% | — | |
| $208.23 | $35.34B | 26.56 | 5.87% | 8.33% | 22.11% | — | |
| $546.29 | $15.6B | 35.75 | 19.97% | 17.19% | 120.89% | — | |
| $168.72 | $12.92B | 58.18 | -0.37% | 5.35% | 4.7% | — | |
| $25.00 | $1.29B | 25.25 | -2.67% | 6.04% | 4.95% | — | |
| $23.66 | $3.83B | 26.58 | -7.16% | 3.71% | 7.39% | — |
Charles River Laboratories International, Inc. (CRL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Charles River Laboratories International, Inc. (CRL) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 11, 2026·SEC
May 7, 2026·SEC
Feb 25, 2026·SEC
Get notified when CRL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Charles River Laboratories International, Inc. (CRL) stock FAQ — growth, dividends, profitability & financials explained
Charles River Laboratories International, Inc. (CRL) reported $4.03B in revenue for fiscal year 2025. This represents a 1983% increase from $193.3M in 1998.
Charles River Laboratories International, Inc. (CRL) saw revenue decline by 0.9% over the past year.
Charles River Laboratories International, Inc. (CRL) reported a net loss of $184.7M for fiscal year 2025.
Charles River Laboratories International, Inc. (CRL) has a return on equity (ROE) of -4.3%. Negative ROE indicates the company is unprofitable.
Charles River Laboratories International, Inc. (CRL) generated $391.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
